Aligos Therapeutics, Inc.
ALGS
$7.22
-$0.43-5.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.89% | 36.96% | -98.81% | -136.82% | 152.45% |
| Total Depreciation and Amortization | 34.63% | 16.82% | -15.06% | 33.51% | -19.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -779.52% | -94.61% | 755.42% | 98.62% | -194.46% |
| Change in Net Operating Assets | 164.50% | -257.57% | 64.73% | 124.25% | -883.33% |
| Cash from Operations | -6.36% | 10.68% | -57.02% | 25.85% | -13.62% |
| Capital Expenditure | 25.00% | 52.33% | -77.06% | -153.49% | -53.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,914.41% | -104.03% | 221.78% | 10.70% | -320.12% |
| Cash from Investing | 1,828.40% | -104.24% | 220.96% | 10.54% | -320.64% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1,966.67% | 70.00% | -900.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 72,572.86% |
| Repurchase of Common Stock | -- | -- | 75.57% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -150.41% | 332.08% | 70.06% | -100.17% | 104,788.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 149.66% | -201.54% | 142.26% | -249.87% | 2,106.84% |